Vittorio Pengo M.D. (CV as of April 2014)



Similar documents
The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases

Thrombosis and Hemostasis

Prior Authorization Guideline

Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

ABOUT XARELTO CLINICAL STUDIES

Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, A. Objective

Backgrounder. Current anticoagulant therapies

DVT/PE Management with Rivaroxaban (Xarelto)

rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc

How To Treat Aneuricaagulation

Lupus anticoagulant Pocket card

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.

The new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

The novel anticoagulants: entering a new era

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

KDIGO THE GEORGE INSTITUTE FOR GLOBAL HEALTH. Antiocoagulation in diabetes and CKD Vlado Perkovic

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

Xarelto (Rivaroxaban)

Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and Antithrombotics From clinical trials to guidelines

Optimal duration of anticoagulation in patients with venous thromboembolism

Investor News. Not intended for U.S. and UK media

CHEST Antithrombotic Therapy and Prevention of Thrombosis, 9 th ed Sarah Meyer, PharmD November 9, 2012

THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

STROKE PREVENTION IN ATRIAL FIBRILLATION

Dabigatran (Pradaxa) Guidelines

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Position Paper on Laboratory Testing for Patients Taking New Oral. Anticoagulants. Consensus Document of FCSA, SIMeL, SIBioC and

Anticoagulation at the end of life. Rhona Maclean

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Disclosures. Overview. Anticoagulation in 2015: Where We Are and Where We Are Going. Impact of NOACs in Canada

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Venous Thromboembolic Treatment Guidelines

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Anticoagulation in Atrial Fibrillation

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

CDEC FINAL RECOMMENDATION

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle?

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain

New Oral Anticoagulants

The author has no disclosures

New Oral Anticoagulants. How safe are they outside the trials?

Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.

Anticoagulant therapy

How To Treat Apl

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Pulmonary Embolism Treatment Update

Cardiovascular Disease

Executive Summary. Motive for the request for advice

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents

Anticoagulation Initiation,Monitoring and Titration. Ng Heng Joo Department of Haematology Singapore General Hospital

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

New Anticoagulants and GI bleeding

Gruppo di lavoro: Malattie Tromboemboliche

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Long-Term Anticoagulant Therapy: Clinical Decision and Therapeutic Strategies. Kenneth A. Bauer, MD Harvard Medical School Boston, MA USA

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師

New Anticoagulants: When and Why Should I Use Them? Disclosures

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

G: Figure 2. Interpretation of the 95% confidence interval for the effect of treatment in a non-inferiority

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

Transcription:

Vittorio Pengo M.D. (CV as of April 2014) Professor of Cardiovascular Medicine, Department of Cardiac Thoracic and Vascular Sciences, and Director of Thrombosis Center, University of Padova School of Medicine, Padova Italy Mailing Address: Clinical Cardiology, Thrombosis Center, via Giustiniani 2, 35128 Padova Italy M.D. degree University of Padova 1974 Residency Internal Medicine, University of Padova Certification Internal Medicine 1980 Cardiology 1985 Post Graduate training Clinical Medicine 1974-1983 Research Fellow, Cardeza Foundation, Philadelphia, PA, USA 1984-1985 Visiting scientist, Cardeza Foundation, Philadelphia, PA, USA, 1988 Clinical Cardiology 1988- Clinical Interests Research Interests Primary/secondary prevention and treatment of venous and arterial thromboembolism Pathophysiology and treatment of thrombosis Reviwer for the following Journals: New England Journal of Medicine, Circulation, Lancet, Blood, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, Thrombosis Research, American Journal of Cardiology, Haematologica, American Journal of Hematology, Journal of Cardiovascular Medicine, European Journal of Clinical Investigation, European Journal of Internal Medicine, Canadian Medical Association Journal Associate Editor of Internal and Emergency Journal since 2011 235 original papers in International Journals (Pub Med) Total Citations: >8000 and H index: 44 (Scopus). Padua, September 4, 2014 1

Major Publications Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russel Viper Venom Time for the diagnosis of the lupus anticoagulant. Blood 1986;68:869-74. Pengo V, Thiagarajan P, Heine M, Shapiro SS. Immunological specificity and mechanism of action of IgG lupus anticoagulant.blood 1987;70:69-76. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995;73:29-34. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721-4. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaboratory study (ISCOAT). Lancet 1996;348:423-28. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, John N, Noventa F, Dalla Volta S. Effectiveness of fixed mini-dose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998;82:433-7. Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-- 2 Glycoprotein I antibodies with Lupus Anticoagulant activity. Blood 1999;94:3814-9. Palareti G, Hirsh J, Legnani C, Manotti C, D Angelo A, Pengo V, Moia M, Guazzaloca G, Musolesi S, Coccheri S. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. 2

Arch Inten Med 2000;160:470-81. Pengo V, Lensing AWA, Prins M, Marchiori A, Davidson B, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P. High incidence of symptomatic chronic pulmonary hypertension after symptomatic pulmonary embolism. N Engl J Med 2004;250:2257-64. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006 Oct 26;355(17):1780-9. Amadeus Investigators, Bousser MG, Bouthier J, Büller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Torp- Pedersen C, Wyse DG.Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008 Jan 26;371(9609):315-21. Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009;119:2920-7. Pengo V, Noventa F, Denas G, Pengo MF, Gallo U, Grion AM, Iliceto S, Prandoni P. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood. 2011;117:1707-9. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714-8. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C; Italian Federation of Thrombosis Centers. 3

Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011 Nov;106(5):868-76. Pengo V. Laboratory tests during direct oral anticoagulant treatment? Yes. Intern Emerg Med. 2013 Aug;8(5):371-2. Pengo V, Ruffatti A, Del Ross T, Tonello M, Cuffaro S, Hoxha A, Banzato A, Bison E, Denas G, Bracco A, Padayattil Jose S. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013 Aug;11(8):1527-31. Pengo V, Marongiu F; Members of the Steering Committee of the Italian Federation of Thrombosis Centers FCSA. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal. J Thromb Haemost. 2013 Jun;11(6):1205-6. Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev. 2013 Jun;12(8):832-4. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost. 2012 Jun;38(4):322-7. Associate Editor: Internal and Emergency Journal since 2011 4

5